Skip to main content
PACS
NYSE Life Sciences

Q3 Revenue Up 11.5%, Adjusted EBITDA Up 33.6%; Full-Year EBITDA Guidance Raised to $685-695M

Tom Rudovsky · Reported by BusinessWire
More coverage: Healthcare Facility Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$46.68
Mkt Cap
$7.391B
52W Low
$10.31
52W High
$50.38
52W Position info
353% above low
Off High info
7.3% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

PACS has more than doubled off its 52-week low of $10.31.

Summary

PACS beat its own trajectory with Q3 revenue of $1.50 billion, up 11.5%, and Adjusted EBITDA of $175.7 million, up 33.6% — EBITDA growth running roughly three times revenue growth. Adjusted EPS came in at $0.63, up 37.0% year-over-year, while GAAP diluted EPS was $0.37. The bigger news is guidance: management raised full-year 2026 Adjusted EBITDA to $685-695 million from $640-660 million and revenue to $5.95-6.05 billion from $5.75-5.85 billion, with the EBITDA midpoint implying about 37% growth over 2025. That raise includes roughly $5 million of retroactive Ohio quality incentive payments received in October, so a slice of the beat is one-time. Growth is also real on the ground: the 32-facility Florida acquisition closed October 1 and the 11-facility Texas deal closed November 1, pushing the portfolio to 398 operations across 21 states. Cash flow remains strong at $583.1 million from operations through nine months, with $707.4 million of liquidity and net leverage of 0.2x. The earnings call is November 4 at 11:30 a.m. ET.

At the time of this announcement, PACS was trading at $46.68 on NYSE in the Life Sciences sector, with a market capitalization of approximately $7.4B. The 52-week trading range was $10.31 to $50.38. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

PACS - Latest Insights

PACS
Nov 03, 2026, 4:17 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $46.68
Real-time Price: $47.22 info
Change: +$0.540 (+1%) info
Market Cap: $7.496B info
PACS
Nov 03, 2026, 4:16 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $46.68
Real-time Price: $47.22 info
Change: +$0.540 (+1%) info
Market Cap: $7.496B info
PACS
Sep 21, 2026, 4:16 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $42.06
Real-time Price: $47.22 info
Change: +$5.16 (+12%) info
Market Cap: $7.496B info
PACS
Sep 01, 2026, 4:16 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $42.14
Real-time Price: $47.22 info
Change: +$5.08 (+12%) info
Market Cap: $7.496B info
PACS
Aug 04, 2026, 4:45 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $45.15
Real-time Price: $47.22 info
Change: +$2.07 (+5%) info
Market Cap: $7.496B info